Cargando…
Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial
Chagas cardiomyopathy is the most frequent and most severe manifestation of chronic Chagas disease, and is one of the leading causes of morbidity and death in Latin America. Although the pathogenesis of Chagas cardiomyopathy is incompletely understood, it may involve several mechanisms, including pa...
Autores principales: | Rassi, Anis, Marin, José Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto Oswaldo Cruz, Ministério da Saúde
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319366/ https://www.ncbi.nlm.nih.gov/pubmed/28225900 http://dx.doi.org/10.1590/0074-02760160334 |
Ejemplares similares
-
The challenge of risk assessment in the riddle of Chagas heart disease
por: Marin-Neto, José Antonio, et al.
Publicado: (2022) -
Deficient Regulatory T Cell Activity and Low Frequency of IL-17-Producing T Cells Correlate with the Extent of Cardiomyopathy in Human Chagas' Disease
por: Guedes, Paulo Marcos Matta, et al.
Publicado: (2012) -
Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
por: Olivera, Mario J., et al.
Publicado: (2017) -
Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil
por: Ferreira, Ariela Mota, et al.
Publicado: (2016) -
A Latin American Man with Palpitations, Dizziness, Episodes of Nonsustained Ventricular Tachycardia, and an Apical Aneurysm
por: Rassi, Anis, et al.
Publicado: (2011)